Bausch+Lomb Results Presentation Deck

3Q22 Financial Highlights & Segment Drivers Organic Revenue Growth ¹.2 in All Three Segments Despite Inflation and FX Headwinds ● Total Company Revenue Millions USD • 949 3Q21 942 3Q22 +5% organic revenue ¹,2 growth Sixth consecutive quarter of organic revenue growth • COVID recovery progressing in China Recession resilient portfolio, able to absorb slower consumer activity and continue growth BAUSCH + LOMB Vision Care . 63% $598M 37% Contact Lens ■Consumer Surgical 27% 54% $172M 19% ■ Implantables ■ Equipment Consumables/Other 3 Q 22 +4% Strong demand for key franchises: Lumify (+7% reported revenue growth) Ocuvite® + PreserVision (+14% reported revenue growth) Daily SiHy (+8% reported revenue growth) Bausch+Lomb ULTRA® (+7% reported revenue growth) • Bio True ONEday (+2% reported revenue growth) 1. This is a non-GAAP measure or ratio. See Slide 2 and Appendix for further information on non-GAAP measures and ratios. 2. Organic revenue growth/change, a non-GAAP ratio, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations. 3. IQVIA NPA monthly. U.S. only. ORGANIC REVENUE +8% Growth in implantables (+4% reported revenue growth; +14% organic revenue growth ¹.2), driven by premium and standard IOLS • Strong demand for consumables (-2% reported revenue decline; +6% organic revenue growth ¹.2), driven by increase in cataract and retina procedures . Ophthalmic Pharmaceuticals . 39% $172M U.S. International CHANGE 61% 1,2 +5% Strong performance in international portfolio (+3% reported revenue growth; +15% organic revenue growth 1.2) Vyzulta® saw 29% TRx growth ³ in 3Q22 Positive early stages of XIPERE® launch 8

View entire presentation